The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Generic Drug Group Sues to Block Maryland Price-Gouging Law

Generic Drug Group Sues to Block Maryland Price-Gouging Law

July 7, 2017 • By Nate Raymond

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—The main U.S. trade group for generic pharmaceutical companies filed a lawsuit on Thursday seeking to block a recently adopted Maryland law that lets the state attorney general sue generic drugmakers that sharply raise prices.

You Might Also Like
  • Drug Industry on Tenterhooks as Maryland Price-Gouging Law Nears
  • Maryland Lawmakers Approve Bill to Fight Drug Price-Gouging
  • Drug Industry Group Sues to Stop California Drug Price Law

The Association for Accessible Medicines filed the lawsuit in federal court in Baltimore to seek an injunction that would block state officials, including Maryland Attorney General Brian Frosh, from enforcing the law.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“If this new law goes into effect, it will harm patients and our communities by reducing choice and limiting access to essential medicines that people need,” Chip Davis, the group’s chief executive, said in a statement.

A spokeswoman for Frosh’s office said it had just received the lawsuit and will review it.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The measure was passed by Maryland’s Democrat-controlled legislature in April amid concerns about rising U.S. drug costs. Governor Larry Hogan, a Republican, said in May that he would allow it to take effect without his signature.

The bill allows Maryland’s state authority on Medicaid, a federal healthcare program for the poor, to let the attorney general’s office know when it sees patients being charged an “unconscionable increase” for essential generic drugs.

The attorney general could then seek an explanation from the manufacturer and sue to protect consumers, with a fine of up to $10,000 for each violation. A judge could order the company to reverse its price increase.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The Association for Accessible Medicines, which represents companies such as Teva Pharmaceutical Industries Ltd and Mylan NV, was formerly known as the Generic Pharmaceutical Association.

In its lawsuit, the association argued that the law, if allowed to take effect as scheduled in October, would grant Maryland unprecedented powers to regulate the national drug market in violation of the U.S. Constitution.

The group said the law would unleash a potentially unlimited number of lawsuits seeking to punish generic drugmakers for prices charged for drugs made available in the state.

It also said the law was unconstitutional because of what it said was a vague prohibition on “price gouging” that provides drugmakers no meaningful description of what it covers.

The group estimated that generic drugs saved Maryland $4.1 billion in 2016.

The case is Association for Accessible Medicines v. Frosh, et al, U.S. District Court, District of Maryland, No. 17-cv-1860.

 

Filed Under: Legal, Pharma Co. News Tagged With: Association for Accessible Medicines, generic pharmaceutical companies, lawsuit, Maryland Attorney General Brian Frosh, Maryland law, rising U.S. drug costs

You Might Also Like:
  • Drug Industry on Tenterhooks as Maryland Price-Gouging Law Nears
  • Maryland Lawmakers Approve Bill to Fight Drug Price-Gouging
  • Drug Industry Group Sues to Stop California Drug Price Law
  • U.S. Judge Throws Out Maryland Bid to Protect Obamacare

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.